STI and beyond: the prospects of boosting anti-HIV immune responses.
Twenty years into the HIV epidemic, highly active antiretroviral therapy (HAART) represents the only effective intervention to control HIV-1 disease progression. However, the prospect of life-long treatment with HAART is challenging given cumulative drug toxicities, difficulties with adherence to complicated regimens and the looming emergence of drug-resistant viruses. The challenges are even greater in resource-poor settings where costs and logistical problems with delivery represent formidable obstacles. Alternative approaches to long-term control of viral replication and disease progression are clearly needed.
Partners AIDS Research Center, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, MA, USA. tallen2@partners.org
Todd M
TM
Allen
Anthony D
AD
Kelleher
John
J
Zaunders
Bruce D
BD
Walker
D000208:Acute Disease; D000818:Animals; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D002908:Chronic Disease; D006678:HIV / Q000276:immunology*; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use
D019380:Anti-HIV Agents; D015215:Zidovudine